Saturday, July 21, 2018

What You Need to Know About Tesla's Big Downgrade Today

Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...

Tesla (NASDAQ:TSLA) stock dropped more than 2% in the opening minutes of trading Thursday, and this time, it wasn't CEO Elon Musk's tweets that were to blame -- or at least not directly.

This time, you can thank Needham & Co. for the sell-off. Here's what you need to know.

Tesla Model X and Model S

Tesla sells electric cars -- but is it selling the right electric cars? Image source: Tesla.

Downgrading Tesla

Early this morning, analysts at the New York-based investment banker downgraded Tesla shares from hold to underperform (Wall Street-speak for "sell"). Needham cited several reasons for its newly bearish stance on the electric-car maker, as outlined in a report on StreetInsider.com (subscription required).

Let's address them in order.

Product mix

Tesla has a lot of irons in the fire, but currently just three car models in mass production: the Model S flagship sedan, the Model X SUV, and the Model 3 "mass market" sedan. Of these, Model S and Model X are believed to be the more profitable models. Problem is, Needham believes that "Model S/X" sales are slowing.

Needham ascribes the decreased sales to "increased competition." The analyst also worries that Model 3 sedans may be causing "possible cannibalization" of sales of Tesla's more profitable models.

On top of all that,�the more electric cars Tesla sells, the closer it gets to the point where the U.S. government will no longer subsidize consumer purchases of those cars with $7,500 electric car tax credits -- a factor that could potentially depress sales across the board.

Give 'em some credit -- please!

Speaking of credits, tax credits for consumers are just one side of the Tesla equation. The company also resells to other manufacturers tax credits it gets for the production of zero-emission vehicles; in some years, such sales account for as much as 19% of its gross profit.

Needham predicts that this ZEV revenue will "decline in 2019," constricting the supply of free government money that Tesla has relied upon to support its race to profitability.

Model 3 problems -- and margin is one

Getting back to the Model 3, though, Tesla recently confirmed it had succeeded in building more than 5,000 Model 3 sedans in a single week -- and promised to soon hit a new level of 6,000 per week. Needham, however, warns Tesla may be failing to reap economies of scale from faster production.

"[G]ross margin improvement" on the Model 3, says Needham, could be "slower" than expected due to "persistently high manufacturing costs" as Tesla does everything and anything it can to hit its numbers (paying workers for overtime for example, and building cars in tents), regardless of whether all these efforts are profitable.

Complicating matters further, Needham notes that its "checks" on the market show that Tesla is experiencing net cancellations of Model 3 orders by customers as "refunds are outpacing deposits." The analyst believes this trend is accelerating,�with as many as 24% of would-be buyers now asking for their money back.

The sun also sets

Meanwhile, Tesla continues to be dogged by fallout from its ill-fated acquisition of SolarCity in 2016. Last month, Tesla announced layoffs of as much as 9% of its workforce, with many job cuts falling in the SolarCity segment of the company's business.

While this might be a good business move, aimed at cutting costs and lowering losses from Tesla's solar power business, Needham explains that it's likely to reduce revenue from solar. Since revenue growth is one of the few metrics investors can examine when deciding whether to invest in unprofitable Tesla, a slowdown in revenue growth can't be good news for the stock.

The most important point

In a coup de grace, Needham ends with a point on Tesla's cash burn.

Tesla burned through $4.1 billion in negative free cash flow last year -- twice its $2 billion reported loss and more than twice the $1.6 billion in negative free cash flow it suffered in 2016, according to data from S&P Global Market Intelligence. Faster Model 3 production is supposed to mitigate cash burn, but Needham believes Tesla will still go through a further $6 billion "through 2020."

The analyst also notes that Tesla has a $1.5 billion debt payment coming due in 2019. Although Tesla has enough cash in the bank ($2.7 billion, according to S&P Global figures) to cover that payment now, continued cash burn will eat away at it, meaning that by the time Tesla's debt comes due, it may not have cash on hand to pay it. That implies additional debt issuance (i.e., paying debt with more debt) or stock sales (i.e., dilution) may be necessary to keep Tesla solvent.

None of this adds up to much of a buy thesis for Tesla stock -- but it may justify a sell.

Thursday, July 19, 2018

Top Medical Stocks To Buy Right Now

tags:PHH,BPT,EDU,TX,KEYS,IONS,

Haemonetics (NYSE: HAE) and Neurometrix (NASDAQ:NURO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Profitability

Get Haemonetics alerts:

This table compares Haemonetics and Neurometrix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Haemonetics 5.04% 12.71% 7.89% Neurometrix -47.75% -161.28% -89.85%

Volatility and Risk

Haemonetics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Neurometrix has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Top Medical Stocks To Buy Right Now: PHH Corp(PHH)

Advisors' Opinion:
  • [By Max Byerly]

    PHH (NYSE:PHH) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 8th. Analysts expect the company to announce earnings of ($0.94) per share for the quarter.

  • [By Logan Wallace]

    PHH (NYSE: PHH) and Orix (NYSE:IX) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

  • [By Stephan Byrd]

    Media headlines about PHH (NYSE:PHH) have been trending somewhat positive recently, Accern Sentiment reports. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PHH earned a news impact score of 0.17 on Accern’s scale. Accern also gave news coverage about the credit services provider an impact score of 45.9794154743809 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

  • [By Max Byerly]

    Orix (NYSE: IX) and PHH (NYSE:PHH) are both finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

  • [By Ethan Ryder]

    New York State Common Retirement Fund decreased its stake in shares of PHH Co. (NYSE:PHH) by 25.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,300 shares of the credit services provider’s stock after selling 9,800 shares during the quarter. New York State Common Retirement Fund’s holdings in PHH were worth $306,000 as of its most recent SEC filing.

Top Medical Stocks To Buy Right Now: BP Prudhoe Bay Royalty Trust(BPT)

Advisors' Opinion:
  • [By Joseph Griffin]

    News headlines about BP Prudhoe Bay Royalty Trust (NYSE:BPT) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BP Prudhoe Bay Royalty Trust earned a daily sentiment score of 0.09 on Accern’s scale. Accern also gave media headlines about the oil and gas company an impact score of 46.2072909143413 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

  • [By Dan Caplinger]

    The stock market had a tumultuous session on Wednesday, as major benchmarks started the day weak but bounced back in the afternoon. Investors weren't happy with the current state of geopolitical uncertainty, with trade disputes threatening to become larger problems than ever. But the release of the minutes of the latest meeting of the Federal Reserve's monetary policy committee convinced many that the central bank will be slow to do lasting damage to the economic expansion, remaining measured in the pace of its interest rate increases. Moreover, some companies had good news that sent their shares higher. Tiffany (NYSE:TIF), BP Prudhoe Bay Royalty Trust (NYSE:BPT), and Ralph Lauren (NYSE:RL) were among the best performers on the day. Here's why they did so well.

  • [By Sean Williams]

    As a case in point, consider BP Prudhoe Bay Royalty Trust (NYSE:BPT), which is currently paying out an extrapolated $5.10 a year, based on the $1.275 per share it divvied out in April. This is good enough for a better than 17% annual yield, albeit it should be noted that the Trust's payout differs each quarter depending on its royalty revenue and cash earnings.�

Top Medical Stocks To Buy Right Now: New Oriental Education & Technology Group, Inc.(EDU)

Advisors' Opinion:
  • [By Motley Fool Staff]

    In the following segment, we dive into the education industry and the artificial intelligence tools being used by New Oriental Education (NYSE:EDU) and Chegg�(NYSE:CHGG) to boost revenue.

  • [By Joseph Griffin]

    Education Management (OTCMKTS: EDMC) and New Oriental Education & Tech Grp (NYSE:EDU) are both consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

  • [By Ethan Ryder]

    EduCoin (EDU) is a PoW/PoS token that uses the Keccak hashing algorithm. It launched on September 9th, 2017. EduCoin’s total supply is 15,000,000,000 tokens. EduCoin’s official website is www.edu.one. EduCoin’s official Twitter account is @PReducoin.

  • [By Ethan Ryder]

    Strayer Education (NASDAQ: STRA) and New Oriental Education & Tech Grp (NYSE:EDU) are both consumer discretionary companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Top Medical Stocks To Buy Right Now: Ternium S.A.(TX)

Advisors' Opinion:
  • [By Logan Wallace]

    Sumitomo (OTCMKTS: SSUMY) and Ternium (NYSE:TX) are both multi-sector conglomerates companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

  • [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday. Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21. MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook. Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06. Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results. Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit. BioTelemetry,
  • [By Logan Wallace]

    TT International cut its position in Ternium (NYSE:TX) by 24.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 865,613 shares of the basic materials company’s stock after selling 277,967 shares during the quarter. Ternium makes up about 1.2% of TT International’s holdings, making the stock its 10th biggest position. TT International owned about 0.43% of Ternium worth $28,123,000 at the end of the most recent reporting period.

Top Medical Stocks To Buy Right Now: Keysight Technologies Inc.(KEYS)

Advisors' Opinion:
  • [By Logan Wallace]

    Keysight Technologies (NYSE: KEYS) and Orbotech (NASDAQ:ORBK) are both computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

  • [By Lisa Levin]

    Thursday morning, the information technology shares surged 0.34 percent. Meanwhile, top gainers in the sector included Keysight Technologies, Inc. (NYSE: KEYS), up 14 percent, and Tech Data Corporation (NASDAQ: TECD) up 8 percent.

  • [By Motley Fool Staff]

    Keysight Technologies Inc. (NYSE:KEYS)Q2 2018 Earnings Conference CallMay 30, 2017, 4:30 p.m. ET

    Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

    Operator

  • [By Lisa Levin] Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) jumped 124.8 percent to $243.725 in reaction to an encouraging Phase 2 clinical trial update. The clinical-stage biopharmaceutical company said its liver-directed, thyroid hormone receptor called MGL-3196 showed a statistical significance in the primary endpoint of lowering liver fat at 12 weeks and also 36 weeks. Viking Therapeutics, Inc. (NASDAQ: VKTX) gained 63.4 percent to $8.12 after falling 4.42 percent on Wednesday. Takung Art Co., Ltd. (NYSE: TKAT) rose 43.3 percent to $2.9094 vTv Therapeutics Inc. (NASDAQ: VTVT) shares climbed 29.7 percent to $2.16 after the company reported a licensing deal with Newsoara Biopharma to rights for vTv's PDE4 Inhibitor in China and other Pacific Rim territories. Akers Biosciences, Inc. (NASDAQ: AKER) gained 26.2 percent to $0.4109. The developer of rapid health information technologies said Wednesday afternoon it was granted a 180-day extension from the Nasdaq Stock Market to meet the requirement of a minimum $1.00 per share closing bid price for 10 straight days. Genprex, Inc. (NASDAQ: GNPX) rose 22.2 percent to $11.6254. Genprex reported engagement of WIRB-Copernicus Group to provide clinical trial services to support Oncoprex clinical trial program. J.Jill, Inc. (NYSE: JILL) gained 21 percent to $7.506 after the company posted upbeat quarterly earnings. Urban One, Inc. (NASDAQ: UONE) gained 19.7 percent to $3.95 after rising 78.38 percent on Wednesday. TapImmune, Inc. (NASDAQ: TPIV) shares gained 18.5 percent to $6.03 after climbing 24.15 percent on Wednesday. Kirkland's, Inc. (NASDAQ: KIRK) rose 17.3 percent to $12.95 after reporting upbeat Q1 results. CymaBay Therapeutics, Inc. (NASDAQ: CBAY) shares gained 15.1 percent to $13.210. The Brink's Company (NYSE: BCO) climbed 14.2 percent to $77.875 as the company announced plans to acquire Dunbar Armored for $520 million in cash. Keysight Technologies, Inc. (NYSE: KEY
  • [By Joseph Griffin]

    OMERS ADMINISTRATION Corp acquired a new stake in shares of Keysight (NYSE:KEYS) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 14,900 shares of the scientific and technical instruments company’s stock, valued at approximately $781,000.

  • [By Lisa Levin]

    Thursday afternoon, the information technology shares surged 0.47 percent. Meanwhile, top gainers in the sector included Keysight Technologies, Inc. (NYSE: KEYS), up 12 percent, and QAD Inc. (NASDAQ: QADB) up 11 percent.

Top Medical Stocks To Buy Right Now: Ionis Pharmaceuticals, Inc.(IONS)

Advisors' Opinion:
  • [By Keith Speights]

    I think there are four primary arguments for buying Biogen stock. One is the company's soon-to-be blockbuster drug Spinraza. The spinal muscular atrophy (SMA) drug, which Biogen licensed from Ionis Pharmaceuticals (NASDAQ:IONS), won Food and Drug Administration approval near the end of 2016. Spinraza�didn't quite hit the $1 billion sales level in 2017, but it's on track to easily top the magic sales mark this year. Analysts think the drug will reach peak annual sales in the ballpark of $2.5 billion.��

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings report�from partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was released�for IONIS-HTTRx, a treatment for Huntington's disease. Biogen managed to end the day in the green, up 1.1%.

  • [By Lisa Levin] Gainers AGM Group Holdings Inc. (NASDAQ: AGMH) shares climbed 30.3 percent to $11.05 after climbing 34.60 percent on Thursday. Limelight Networks, Inc. (NASDAQ: LLNW) jumped 21.2 percent to $4.9699 following a first-quarter earnings beat. The company also raised its fiscal 2018 estimates. Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) shares climbed 18.8 percent to $7.89 after reporting strong Q1 earnings. Farmers Capital Bank Corp (NASDAQ: FFKT) gained 15.4 percent to $48.75. WesBanco Inc (NASDAQ: WSBC) announced an agreement and plan of merger with Farmers Capital Bank Corporation. TransUnion (NYSE: TRU) climbed 10.2 percent to $66.76 after the company posted upbeat Q1 results and issued a strong forecast for the second quarter. TransUnion announced plans to acquire Callcredit. Myomo, Inc. (NYSE: MYO) shares gained 9.2 percent to $3.9299 after rising 8.11 percent on Thursday. Pinnacle Foods Inc (NYSE: PF) gained 8.8 percent to $60.04 after a 13-D filing from Jana Partners showed an increased stake in the comapny, from 1.42 million shares at the end of last quarter to 10.83 million shares, or a 9.3-percent stake. Associated Banc-Corp (NYSE: ASB) shares climbed 8.8 percent to $26.70 following upbeat Q1 earnings. OFG Bancorp (NYSE: OFG) gained 8.5 percent to $12.80 after reporting Q1 results. Cleveland-Cliffs Inc. (NYSE: CLF) climbed 7.5 percent to $7.73 following Q1 results. Seaspan Corporation (NYSE: SSW) shares climbed 6.7 percent to $7.50. Deutsche Bank upgraded Seaspan from Hold to Buy. General Electric Company (NYSE: GE) shares rose 4.6 percent to $14.63 after the company reported better-than-expected earnings for its first quarter. Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) rose 4.3 percent to $47.80. Biogen and Ionis have expanded their strategic collaboration to develop drug candidates for a broad range of neurological diseases.

    Check out these big penny stock gainers and losers

  • [By George Budwell]

    Biogen's top-line growth has now become almost totally dependent on sales of its fairly new spinal muscular atrophy (SMA) drug, Spinraza, that it co-developed with Ionis Pharmaceuticals (NASDAQ:IONS).

Monday, July 16, 2018

Buy Persistent Systems; target of Rs 1200: Dolat Capital


Dolat Capital's research report on Persistent Systems


PSYS reported revenue growth of 5.4% YoY in FY18; software services revenue (contri. 74%) grew by 8.9% YoY in FY18 to ` 22.6bn compared to ` 20.7bn in the previous year, while IP led revenue which contributes 26% of the total revenue declined 3.6% YoY to ` 7,766mn compared to ` 8,060mn in FY17. Increase in earnings by 7% YoY to ` 40.4 during the year was on account of higher other income despite lower EBIT margins.


Outlook
We maintain our BUY rating with TP of ` 1,200 based on 15.5x one yr. fwd. PER.


For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 13, 2018 05:18 pm

Friday, July 13, 2018

Mediwound Ltd (MDWD) Expected to Announce Quarterly Sales of $970,000.00

Analysts expect Mediwound Ltd (NASDAQ:MDWD) to report $970,000.00 in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Mediwound’s earnings, with the highest sales estimate coming in at $1.14 million and the lowest estimate coming in at $740,000.00. Mediwound posted sales of $690,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 40.6%. The company is expected to report its next quarterly earnings results on Thursday, August 2nd.

On average, analysts expect that Mediwound will report full year sales of $3.56 million for the current year, with estimates ranging from $2.79 million to $3.90 million. For the next financial year, analysts anticipate that the company will report sales of $11.69 million per share, with estimates ranging from $5.81 million to $14.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Mediwound.

Get Mediwound alerts:

Mediwound (NASDAQ:MDWD) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.57 million. Mediwound had a negative net margin of 904.12% and a negative return on equity of 226.62%.

Several research firms have weighed in on MDWD. ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Zacks Investment Research lowered shares of Mediwound from a “hold” rating to a “sell” rating in a report on Wednesday. Oppenheimer set a $14.00 target price on shares of Mediwound and gave the stock a “buy” rating in a report on Monday, June 11th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Mediwound in a report on Tuesday, May 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Mediwound currently has a consensus rating of “Buy” and a consensus target price of $9.29.

Large investors have recently modified their holdings of the stock. Meitav Dash Investments Ltd. acquired a new stake in shares of Mediwound during the fourth quarter worth $2,184,000. Wells Fargo & Company MN raised its holdings in shares of Mediwound by 84.6% during the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Mediwound by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 15,500 shares during the period. Institutional investors and hedge funds own 32.78% of the company’s stock.

MDWD opened at $6.45 on Friday. The firm has a market capitalization of $185.28 million, a price-to-earnings ratio of -10.40 and a beta of -0.09. Mediwound has a twelve month low of $3.56 and a twelve month high of $7.50.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Wednesday, July 11, 2018

Amazon And Walmart: Digital Native Vs. Physical Presence

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-613a0c11f7d6406ba684fea423c3a331&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/613a0c11f7d6406ba684fea423c3a331/960x0.jpg?fit=scale&q; data-height=&q;564&q; data-width=&q;960&q;&g; (AP Photo/Elaine Thompson, File)

&l;span&g;&l;a href=&q;https://www.walmart.com/&q; target=&q;_blank&q;&g;Walmart&l;/a&g;&l;/span&g; and &l;span&g;&l;a href=&q;https://www.amazon.com/&q; target=&q;_blank&q;&g;Amazon&l;/a&g;&l;/span&g; are competing in nearly every facet of their businesses. I&a;rsquo;ve written about some areas recently including their &l;span&g;&l;a href=&q;https://www.forbes.com/sites/gregpetro/2018/07/01/build-it-or-buy-it-will-amazon-or-walmart-win-the-retail-innovation-battle/&q;&g;approaches to innovation&l;/a&g;&l;/span&g; and the &l;span&g;&l;a href=&q;https://www.forbes.com/sites/gregpetro/2018/06/24/amazon-replaces-merchants-with-bots-how-levis-wolverine-worldwide-and-saks-can-compete/#18c905545156&q;&g;evolving role&l;/a&g;&l;/span&g; of the merchant within their organizations. Another area that&a;rsquo;s a heavy focus for both organizations? The race to the top for their physical and digital presences.

This race started with Walmart acquiring &l;span&g;&l;a href=&q;https://jet.com/&q; target=&q;_blank&q;&g;Jet.com&l;/a&g;&l;/span&g; in August 2016. This was Walmart&a;rsquo;s direct hit against Amazon&a;rsquo;s web presence and an apparent signal that the company was ready to compete.

It didn&a;rsquo;t take long, though, for Amazon to strike back with an acquisition of &l;span&g;&l;a href=&q;https://www.wholefoodsmarket.com/&q; target=&q;_blank&q;&g;Whole Foods&l;/a&g;&l;/span&g; in June 2017. &l;span&g;&l;a href=&q;https://www.forbes.com/sites/gregpetro/2017/08/02/amazons-acquisition-of-whole-foods-is-about-two-things-data-and-product/#30cfa00aa808&q;&g;As I previously wrote&l;/a&g;&l;/span&g;, the goal of that acquisition was for Amazon to gain more of the rich data behind the Whole Foods customer and to garner all of the private label brands that the grocer had accumulated.

Since last summer, the organization has been looking at ways to leverage that acquisition with services like &l;span&g;&l;a href=&q;https://www.amazon.com/b?ie=UTF8&a;amp;node=6442600011&q; target=&q;_blank&q;&g;Amazon Lockers&l;/a&g;&l;/span&g; and &l;span&g;&l;a href=&q;https://www.amazon.com/b?ie=UTF8&a;amp;node=16008589011&q; target=&q;_blank&q;&g;Amazon Go&l;/a&g;&l;/span&g; to bolster its physical presence.

Much like with ecommerce, convenience is key for shoppers in the physical world. A main priority for Amazon is to shorten the time it takes for a consumer to complete a shopping trip. Amazon Go Is all about creating a frictionless shopping experience. It opened to the public in January 2018 and promised no cashiers or checkout lines and a streamlined shopping experience. This can be extremely beneficial given &l;span&g;&l;a href=&q;https://www.zdnet.com/article/is-amazon-gos-cashier-less-shopping-the-future-of-retail/&q; target=&q;_blank&q;&g;that in the past year&l;/a&g;&l;/span&g;, 86% of U.S. consumers said they left a store due to long lines, resulting in a purchase at a different retailer or no purchase at all according to 451 Research.

Additionally, Amazon Lockers are popping up in all Whole Foods locations. While they offer a convenient way for shoppers to pick-up and return items from Amazon.com, they also increase the likelihood that someone will purchase something in-store while visiting the Locker.

All of this is happening while Amazon continues to bolster its online presence and offerings on its platform. More retailers than ever are selling through the channel, enabling Amazon to see into trends and pricing data and thus make more informed decisions on its own private label brands. More on that in my next article.

&l;!--nextpage--&g;

Walmart on the other hand already has a huge physical network with more than 5,000 stores. The company continues to improve its in-store experience, through technology like its &a;ldquo;&l;span&g;&l;a href=&q;http://www.businessinsider.com/walmart-revamps-app-to-bolster-the-in-store-experience-2018-2&q; target=&q;_blank&q;&g;Store Assistant&l;/a&g;&l;/span&g;&a;rdquo; app. Walmart is also testing &l;span&g;&l;a href=&q;https://blog.walmart.com/innovation/20170512/a-look-inside-walmarts-next-gen-test-stores&q; target=&q;_blank&q;&g;new layout concepts&l;/a&g;&l;/span&g; and drawing people in with entirely revamped &l;span&g;&l;a href=&q;https://www.cnbc.com/2018/02/16/walmart-rolls-out-new-apparel-brands-for-women-kids-and-plus-sizes.html&q; target=&q;_blank&q;&g;private label apparel brands&l;/a&g;&l;/span&g;.

The retailer is making great strides on the ecommerce side as well. Walmart &l;span&g;&l;a href=&q;https://www.cnbc.com/2018/04/16/walmart-to-roll-out-redesigned-website-next-month.html&q; target=&q;_blank&q;&g;recently released&l;/a&g;&l;/span&g; a new streamlined version of its website and mobile app, changing the look and feel while making it easier than ever for consumers to find the deals they know and love from the brand.

Also on the new website, you&a;rsquo;ll find an increased focus on high-end fashion through its &l;span&g;&l;a href=&q;https://www.nytimes.com/2018/05/16/business/walmart-lord-and-taylor-website.html&q; target=&q;_blank&q;&g;partnership&l;/a&g;&l;/span&g; with &l;span&g;&l;a href=&q;http://www.lordandtaylor.com/Entry.jsp&q; target=&q;_blank&q;&g;Lord &a;amp; Taylor&l;/a&g;&l;/span&g;. Both companies expect to see a boost in sales for different reasons. Walmart can now expand beyond everyday-low-priced fashion and attract a higher-end customer. Lord &a;amp; Taylor has expanded their online presence and customer base without incurring a lot of cost.

While all of those are great, I think Walmart&a;rsquo;s best strategy to pull shoppers from Amazon.com is through its free two-day shipping offering. While Amazon offers this to individuals who have a Prime membership, which recently had an &l;span&g;&l;a href=&q;http://fortune.com/2018/01/19/amazon-prime-membership-price/&q; target=&q;_blank&q;&g;18% uptick in cost&l;/a&g;&l;/span&g;, Walmart offers this to all shoppers with no fee. They just have to spend $35 in the transaction.

It&a;rsquo;s really been interesting to watch these two close the gap, and I think it will only continue to heat up. Both will experience major pains as they continue to move into uncharted territory.

I do think that Amazon has gotten so big that they have started to underestimate other retailers, Walmart included. While anyone who has claimed this success certainly deserves the accolades, a massive ego provides an opportunity for a competitor. Seattle and Silicon Valley seem to have no shortage of ego whether supported by results or not.

The battle continues.&l;/p&g;

Tuesday, July 10, 2018

Bitcoin is down 66%. But it still may be the future of money

The bubble may have burst for bitcoin and other cryptocurrencies.

The price of one bitcoin is now hovering around $6,400. That's a more than 50% drop in 2018 and a 66% plunge from the all-time high of just under $20,000 that bitcoin hit in late December.

Other cryptocurrencies, such as Ethereum, XRP (aka Ripple) and Litecoin, have suffered similar gut-wrenching drops in the past few months.

Legendary investors Warren Buffett and Charlie Munger of Berkshire Hathaway (BRKB) have warned investors to stay away from cryptocurrencies as a result.

Buffett told CNBC in early May bitcoin was "probably rat poison squared" while Munger said at at the Berkshire shareholder meeting that the thought of owning cryptocurrencies was "just dementia."

Bitcoin may eventually bounce back. Blockchain technology could still transform how people pay for things in the future.

But the scores of other cryptocurrencies that have cropped up in bitcoin's wake may not thrive -- or even survive.

"The market did go up a little too much last year and people felt it was easy to make money. Investors weren't separating the good from the bad," said Ben Marks, CEO and founder of Blocktrade Capital, a firm that trades cryptocurrencies. "But bitcoin is definitely here to stay."

Cryptocurrencies' rise had all the signs of a bubble. Tons of publicly traded companies tried to latch onto the crypto craze.

Bioptix, a maker of hormones for farm animals changed its name to Riot Blockchain (RIOT). The stock surged -- until the company disclosed the Securities and Exchange Commission was probing it.

Beverage company Long Island Iced Tea morphed into Long Blockchain (LBCC). It's since been delisted by the Nasdaq and now trades as a so-called bulletin board stock at a price below 50 cents a share.

Making matters worse: Some companies began selling digital tokens to raise money.

Eastman Kodak (KODK) -- yes, the camera and film company -- created its own KodakCoin. There's even a PotCoin for the legal marijuana and cannabis industry.

Some of these so-called initial coin offerings are legitimate. But there have been plenty of scams too. The SEC created a fake ICO called HoweyCoins to show how easy it is for investors to get duped.

The sheer number of crypto offerings is very similar to how Pets.com, Webvan, Garden.com and tons of other e-commerce stocks ultimately went under when the dot-com bubble burst in 2000.

We didn't need hundreds of internet retailers. Even Amazon's shares were hit hard in the immediate wake of the tech bust because of concerns about its lack of profit and insane valuation.

But Amazon (AMZN) eventually started to make money as it expanded into more areas and got people to begin paying subscriptions for Prime memberships.

As Amazon became increasingly dominant, other big retailers like Walmart (WMT), Best Buy (BBY) and Kroger (KR) adapted their business models so they too could get a piece of the digital pie.

That's been great for consumers -- and the shareholders of large brick and mortar retailers. But it shows that having an e-commerce strategy isn't special. Its a vital part of any retailer's strategy.

The same may ultimately be said for bitcoin and the blockchain.

Blocktrade Capital's Marks said that mainstream companies in the health care and entertainment industries could use blockchain digital ledgers to modernize their record keeping.

Big banks are taking notice too. Goldman Sachs (GS) has said it will begin futures trading in bitcoin contracts, a move that should ultimately be good for bitcoin and other leading cryptocurrencies that rely on blockchain.

"Volatility may decrease, which isn't great for traders and speculators, but the involvement of Goldman Sachs and other big Wall Street firms is good for the long-term. It's a seal of approval," Marks said.

Thursday, July 5, 2018

Best Stocks To Own Right Now

tags:DISCB,INAP,BMRN,

Spring forward. Fall back. It��s an amusing little mnemonic relating to Daylight Saving Time, indicating that clocks are moved forward an hour in spring and back an hour in autumn. But there��s nothing funny about falling at any age.

Many people think falls are a normal part of aging. They��re not. And there are more than a few people and organizations who have set out to debunk this common myth and educate individuals of all ages about how serious falls can be and how to avoid them.

Now in its 10th year, ��National Falls Prevention Awareness Day�� (FPAD) is a nation-wide effort by the National Council On Aging (NCOA) and countless others to bring attention to this growing public health issue and how to prevent fall-related injuries among older adults.

Every year on the first day of fall, they celebrate FPAD to bring attention to this growing public health issue. Today is that day.

(Photo Courtesy of NCOA)

NCOA 2015 Falls Free® Photo Contest Honorable Mention winner First Baptist Church of Glenarden; Landover, Maryland.

Best Stocks To Own Right Now: Discovery Communications, Inc.(DISCB)

Advisors' Opinion:
  • [By Max Byerly]

    Discovery (NASDAQ:DISCB) announced its quarterly earnings results on Tuesday. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.13, Morningstar.com reports. Discovery had a negative net margin of 7.40% and a positive return on equity of 19.34%. The company had revenue of $2.31 billion for the quarter.

  • [By Billy Duberstein]

    You might think�Discovery Inc.'s (NASDAQ:DISCA) (NASDAQ:DISCK) (NASDAQ:DISCB) stations primarily feature nature videos and celebrity cooks, but did you know it's actually becoming a player on the international sports scene? While known for its namesake Discovery Channel and documentary brands such as The Learning Channel, HGTV, and the Food Network, Discovery has actually been in the sports business since 2012, when it first acquired a minority stake in European sports channel Eurosport. Discovery was apparently pleased enough with the channel's progress to buy 100% of Eurosport in July 2015, and that year, Eurosport won the exclusive rights to broadcast the Olympics in Europe from 2018-2022.

Best Stocks To Own Right Now: Internap Network Services Corporation(INAP)

Advisors' Opinion:
  • [By Stephan Byrd]

    Internap Corp (NASDAQ:INAP) has received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $28.00.

  • [By Stephan Byrd]

    Internap (NASDAQ:INAP) issued its quarterly earnings data on Thursday. The information technology services provider reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13), MarketWatch Earnings reports. The business had revenue of $74.20 million for the quarter, compared to analyst estimates of $73.99 million. Internap had a negative return on equity of 271.76% and a negative net margin of 16.15%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Internap (INAP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Stocks To Own Right Now: BioMarin Pharmaceutical Inc.(BMRN)

Advisors' Opinion:
  • [By Chris Lange]

    BioMarin Pharmaceutical Inc.’s (NASDAQ: BMRN) first-quarter results are due late on Wednesday. The consensus forecast calls for a net loss of $0.18 per share and revenue of $348.57 million. The shares ended last week at $82.30. The consensus analyst target is $114.30. The 52-week trading range is $75.81 to $100.51.

  • [By ]

    BioMarin Pharmaceutical (Nasdaq: BMRN) is a leader in the orphan drug category (drugs used to treat rare diseases), which gives it extended protection and a longer sales trajectory versus other pharmaceuticals. The company is expected to bring its PKU treatment Pegvaliase to market this year to add significantly to sales and blockbusters Vosoritide and Valrox could come to market within the next two years.

  • [By Ethan Ryder]

    News articles about BioMarin Pharmaceutical (NASDAQ:BMRN) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.3333460791898 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Logan Wallace]

    BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 309 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Monday, May 7th. The stock was sold at an average price of $85.96, for a total transaction of $26,561.64. Following the transaction, the executive vice president now directly owns 53,223 shares in the company, valued at approximately $4,575,049.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

  • [By Todd Campbell]

    I'm always on the lookout for fast-growing stocks to include in my retirement portfolio. Recently, I bought shares in Paycom Software, Inc.�(NYSE:PAYC), BioMarin Pharmaceutical (NASDAQ:BMRN), and 2U Inc. (NASDAQ:TWOU). Are these stocks right for your portfolio, too?�Read on to learn why I think these companies can deliver market-beating returns.

Wednesday, July 4, 2018

Fantomcoin (FCN) Price Tops $0.13 on Exchanges

Fantomcoin (CURRENCY:FCN) traded up 3.3% against the US dollar during the twenty-four hour period ending at 0:00 AM ET on July 2nd. Fantomcoin has a market capitalization of $917,011.00 and $4,405.00 worth of Fantomcoin was traded on exchanges in the last 24 hours. One Fantomcoin coin can currently be bought for approximately $0.13 or 0.00001900 BTC on major exchanges. During the last seven days, Fantomcoin has traded down 30% against the US dollar.

Here’s how similar cryptocurrencies have performed during the last 24 hours:

Get Fantomcoin alerts: Dero (DERO) traded up 3.4% against the dollar and now trades at $1.11 or 0.00016759 BTC. Masari (MSR) traded up 17% against the dollar and now trades at $0.27 or 0.00004130 BTC. Dinastycoin (DCY) traded 5.1% higher against the dollar and now trades at $0.0004 or 0.00000006 BTC. Dashcoin (DSH) traded 13.9% higher against the dollar and now trades at $0.0205 or 0.00000309 BTC. QuazarCoin (QCN) traded flat against the dollar and now trades at $0.0153 or 0.00000200 BTC. Bitcedi (BXC) traded down 0.7% against the dollar and now trades at $0.0099 or 0.00000109 BTC. BipCoin (BIP) traded up 8.2% against the dollar and now trades at $0.0321 or 0.00000483 BTC.

Fantomcoin Profile

Fantomcoin (FCN) is a proof-of-work (PoW) coin that uses the
Cryptonight hashing algorithm. It launched on May 6th, 2014. Fantomcoin’s total supply is 7,272,036 coins. The official website for Fantomcoin is fantomcoin.org. Fantomcoin’s official Twitter account is @fantomcoin.

Buying and Selling Fantomcoin

Fantomcoin can be purchased on the following cryptocurrency exchanges: HitBTC. It is usually not possible to purchase alternative cryptocurrencies such as Fantomcoin directly using U.S. dollars. Investors seeking to trade Fantomcoin should first purchase Bitcoin or Ethereum using an exchange that deals in U.S. dollars such as GDAX, Gemini or Coinbase. Investors can then use their newly-acquired Bitcoin or Ethereum to purchase Fantomcoin using one of the aforementioned exchanges.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “FCNUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Monday, July 2, 2018

Brokerages Set Kornit Digital Ltd (KRNT) Price Target at $20.50

Kornit Digital Ltd (NASDAQ:KRNT) has been assigned a consensus rating of “Buy” from the nine analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $20.50.

A number of brokerages have recently commented on KRNT. Canaccord Genuity lifted their target price on shares of Kornit Digital from $18.00 to $20.00 and gave the company a “buy” rating in a report on Friday, June 8th. Stifel Nicolaus began coverage on shares of Kornit Digital in a research report on Thursday, June 7th. They issued a “buy” rating and a $21.00 price objective on the stock. BidaskClub upgraded shares of Kornit Digital from a “sell” rating to a “hold” rating in a research report on Friday, May 11th. Finally, Zacks Investment Research upgraded shares of Kornit Digital from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 18th.

Get Kornit Digital alerts:

Shares of Kornit Digital stock traded up $0.05 during trading on Monday, reaching $17.80. The company’s stock had a trading volume of 165,690 shares, compared to its average volume of 246,401. The stock has a market capitalization of $608.95 million, a price-to-earnings ratio of 147.92 and a beta of 0.30. Kornit Digital has a fifty-two week low of $11.70 and a fifty-two week high of $21.80.

Kornit Digital (NASDAQ:KRNT) last announced its earnings results on Tuesday, May 8th. The industrial products company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.08. The business had revenue of $31.10 million for the quarter, compared to analysts’ expectations of $29.42 million. Kornit Digital had a net margin of 0.24% and a return on equity of 2.54%. The company’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) EPS. equities analysts expect that Kornit Digital will post 0.25 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its position in shares of Kornit Digital by 973.6% during the 4th quarter. Wells Fargo & Company MN now owns 8,546 shares of the industrial products company’s stock worth $138,000 after purchasing an additional 7,750 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of Kornit Digital by 5.0% during the 4th quarter. Schroder Investment Management Group now owns 856,945 shares of the industrial products company’s stock worth $13,840,000 after purchasing an additional 40,919 shares in the last quarter. BlackRock Inc. boosted its position in shares of Kornit Digital by 10.4% during the 4th quarter. BlackRock Inc. now owns 330,307 shares of the industrial products company’s stock worth $5,334,000 after purchasing an additional 31,052 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Kornit Digital during the 4th quarter worth $186,000. Finally, Senvest Management LLC boosted its position in shares of Kornit Digital by 16.8% during the 4th quarter. Senvest Management LLC now owns 1,530,177 shares of the industrial products company’s stock worth $24,712,000 after purchasing an additional 220,000 shares in the last quarter. Hedge funds and other institutional investors own 92.17% of the company’s stock.

About Kornit Digital

Kornit Digital Ltd. develops, manufactures, and markets industrial digital printing technologies for the garment, apparel, and textile industries. The company focuses on the direct-to-garment and roll-to-roll segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software, and value added services.

Analyst Recommendations for Kornit Digital (NASDAQ:KRNT)